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Optimizing compliance, efficiency, and
safety during surveillance of small abdominal
aortic aneurysms
Paul A. Armstrong, DO, Martin R. Back, MD, Dennis F. Bandyk, MD, Ann S. Lopez, ARNP,
Shelly K. Cannon, ARNP, Brad L. Johnson, MD, and Murray L. Shames, MD, Tampa, Fla
Background: Outcome data documenting safety for observation of small abdominal aortic aneurysms (AAA 4.0 to 5.4 cm)
are lacking outside of large clinical trials but requires near perfect patient compliance. This study describes a clinical
pathway for AAA surveillance using a prospective database utilizing a nurse practitioner oversight to provide efficient use
of clinic visits while maintaining a high level of patent participation.
Methods: Over a 7-year period (June 1999 through June 2006), 334 patients were enrolled in an AAA surveillance
pathway at our academic veterans hospital. To minimize patient travel, clinic visitation was reserved for an initial
examination with patient education and for discussion of intervention options in patients demonstrating AAA growth
(>5.4 cm or expansion >1 cm/yr) during follow-up. Biannual ultrasound or CT imaging was scheduled and results
discussed (after physician review) via telephone or “same day” direct patient contact. An electronic database was used to
update patient information and plan follow-up.
Results: Compliance with the AAA surveillance pathway was achieved in 98.5% of patients, with only three patients (0.9%)
lost to follow-up and two others (0.6%) choosing early repair at civilian institutions. At a mean interval of 29 months
(20 mo), surgical repair was performed in 225 (67%) patients by open (n  143) or endovascular (n  82) techniques
for AAA growth to >5.4 cm (n  219) or expansion by >1cm/yr (n  6). One hundred six patients currently remain in
surveillance. A single AAA rupture resulting in death occurred during surveillance (0.3%) and perioperative mortality
(<60 days) was 0.9% in patients needing intervention for AAA growth. Cumulative aneurysm-related mortality was 0.9%
for patients compliant with the AAA surveillance pathway.
Conclusions: Use of a prospectively-maintained surveillance database managed by a non-physician provider with a reliance
on telephone contact resulted in a high degree of patient compliance, reduced unnecessary patient travel, and provided
practical clinic use. Limited additional resources were needed to implement our pathway and a similar approach may prove
useful for large volume hospital, clinic, or practice systems. ( J Vasc Surg 2007;46:190-6.)The United Kingdom (UK) Small Aneurysm Trial and
the Aneurysm Detection and Management Study (ADAM)
provided an initial valuable foundation for recommended
management of small abdominal aortic aneurysms (AAA).1-5
Both trials demonstrated that observation could be safely
employed in compliant patients for 4.0 to 5.4 cm diameter
AAAs with a low associated annual risk of rupture (0.6%3 to
1.0%2) compared with immediate elective open repair.
Outside of prospective trials requiring patient consent at
entry to comply with an assigned treatment regime, there
are few reports detailing the safety of small AAA surveil-
lance in general medical practice.6,7 Valentine et al6 showed
that failure of patient compliance with surveillance oc-
curred in one-third of a regional veterans population. “Lost
to follow-up” was associated with a greater than 10% risk of
AAA rupture and a lower overall survival rate compared to
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190compliant patients. Failure of follow-up was due to numer-
ous patient-related factors and physician/medical center
deficiencies including transportation/travel distance diffi-
culties, poor patient motivation, inadequate patient coun-
seling, and reliance on primary care for patient education
and nonoperative AAA management. Based on similar con-
cerns at our academic Veterans Administration (VA) med-
ical center, in 1999 the vascular surgery division devised
and directed a clinical pathway for small AAA surveillance
utilizing vascular practitioners to assume management of a
prospectively-maintained patient AAA database, provide
patient education, and coordinate surveillance imaging
with a focus on minimizing clinic follow-up visits by “one-
stop” imaging and evaluation, and reliance on telephone
communication. This report describes the implementation
of an AAA surveillance clinical pathway aimed at improving
patient participation while providing satisfactory clinical
outcomes for aneurysm related morbidity and mortality.
METHODS
Population. The James A. Haley Veterans Hospital
(JAHVH) is a 327-bed tertiary care, academic medical
center in Tampa, Florida with a “catchment” range of 250
miles spanning eight counties over central Florida and
serving a veteran population of approximately 436,000.
Prior to 1998, there was no organized method to track
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rolled in the observation arm of the ADAMS trial (n  32),
and most of ongoing surveillance was relegated to the
primary practitioner physician assigned to each veteran’s
care.
AAA imaging and measurement. In mid 1999, we
implemented a clinical pathway to manage all patients
found to have aortic aneurysms within our hospital system.
Our vascular surgery service receives between four to eight
new consultations for aortoiliac ectasia/aneurysm per
month. The initial imaging exam as ordered by the primary
VA practitioner was variable and included patients who
were being screened for AAA, patients with known AAA
but were new to the Veterans Health System, or patients
being imaged for other abdominal pathology.
All initial imaging studies (abdominal ultrasound [US],
computed tomography [CT], or magnetic resonance imag-
ing [MRI]) were physician reviewed (M.R.B., P.A.A.) in
order to arrive at an accurate description of the aneurysm
location and size prior to any clinic visitation. Aneurysm
size was determined by recording the maximal cross-
sectional diameter as measured perpendicular to the direc-
tion or tortuosity of the aorta. In general, 3 to 4 cm
diameter AAA were followed by yearly US, and 4 to 5.4 cm
diameter AAA were followed biannually with US or CT
scans. Due to some disparity and variability (up to 10 mm vs
CT measures) in US studies interpreted in our hospital’s
radiology department,8,9 at least a single CT scan was
performed for all AAA 4.5 cm to confirm accurate aortic
sizing and included chest, abdominal and pelvic imaging of
the entire aorto-iliac system. Fusiform AAA 5.4 cm,
saccular AAA 5.0 cm, iliac aneurysms 4.0 cm, and any
AAA with 1.0 cm annual growth documented by CT scan
and occurring in adequate medical risk patients were con-
sidered for either endovascular (if anatomically feasible) or
open repair. Occasional patients with extremely high med-
ical risk and not felt to have anatomy amenable to endovas-
cular repair were imaged at 6-month intervals until AAA
growth to 6.0 cm. Almost no patient was denied interven-
tion for a large AAA based solely on severity of comorbidi-
ties. Although we performed surveillance for many aortic
pathologies including chronic type B dissections, para-
anastomotic/recurrent aneurysms, postendovascular re-
pairs, thoracic and thoracoabdominal aneurysm, pararenal
aortic and isolated iliac (de novo) aneurysms, and 3 to 4 cm
AAA, this report focused on management of 473 veterans
(99% male) entering the pathway with infrarenal AAA 4.0
cm. This included 85 (18%) known AAA experiencing
growth from a smaller size, 94 (20%) patients with AAA
suggested by physical exam, 23 (5%) AAA found as a result
of familial screening, and 271 (57%) AAA found inciden-
tally by various imaging studies done for nonvascular symp-
tomatology. Patients presenting on their initial consulta-
tion with symptomatic aneurysms or size 5.4 cm who
were good operative risk were excluded from final outcome
analysis.
Clinical pathway. As part of their clinical duties on
our vascular service, an advanced registered nurse practitio-ner (ARNP) receives, evaluates and responds to all new
AAA consults, schedules all imaging studies, and reviews
all completed studies with attending vascular surgeons
(M.R.B., P.A.A.) to confirm AAA measurements. After
imaging review, the surveillance or treatment plan is up-
dated and the ARNP arranges needed clinic visitations,
maintains telephone contact with patients during surveil-
lance or intervention planning, and enters and updates
patient and AAA information into a database. A compre-
hensive medical record is available for all veterans through a
national computerized patient record system (CPRS) that
also permits tracking of AAA consultations and ongoing
communication with referring practitioners and primary
care physicians. In general, after surgeon imaging review of
4.0 cm AAA imaging studies, initial telephone contact
was made with the patient by the ARNP, and brief (5
min) education of AAA disease and recommended treat-
ment was provided. All patients with AAA 5.4 cm were
seen within 2 weeks in clinics by attending surgeons and the
contacting ARNP for operative consideration. While not
mandatory, patients with 4.0 to 5.4 cm AAA were offered
an initial clinic appointment for further education, physical
examination, and discussion of planned surveillance. Pa-
tient’s family members or close friends were encouraged to
attend clinic visits to assure more complete questioning and
potential retention of discussed information. Printed AAA
educational materials were provided and the patients were
given contact phone numbers to the vascular office and
ARNP for addressing further issues.
For AAAs continued under surveillance, serial US or
CT studies were scheduled by the ARNP either at our
hospital or other VA outpatient clinics with imaging capa-
bilities to accommodate potential patient transportation
limitations and minimize travel distances. Appointment
scheduling was arranged by telephone contact and confir-
mations mailed to patients. Most of the completed studies
could be viewed at a hospital computer workstation of the
electronic storage system for imaging performed at most
VA-related facilities within the VISN 8 (central Florida)
network. After physician review of imaging, study results,
further management plan, and surveillance scheduling were
conveyed to patients via phone by the ARNP within 1to 2
weeks. For some studies performed at our hospital and
immediately available for review, patients were seen in our
clinic/office the same day of imaging and results discussed.
If a patient failed to return telephonemessages left for them
or missed an imaging study, a letter was mailed with de-
tailed instructions for further planned follow-up. Further
attempts at direct telephone contact were continued at
monthly intervals with “lost to follow-up” designated after
more than 3 months of failed telephone and mailed con-
tact. Clinic visitations were avoided during surveillance of
small AAA unless specifically requested by patients. The
AAA surveillance clinical pathway is detailed diagrammati-
cally in Fig 1.
Surveillance database. Using a standard Microsoft
Access program (Redmond, Wash), a database template
was created that prospectively records patient demograph-
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initial study and imaging modality, current AAA diameter,
date of next imaging and status of study ordering/sched-
uling, and a comments box where we have detailed addi-
tional imaging findings. Through menu drop-down op-
tions specific database queries can be performed including
listing of AAA studies due for review and listing of all AAA
5.0 cm (nearing consideration for intervention). The
database was queried every 1 to 2 weeks to generate a list of
patients due for AAA imaging review and missed appoint-
ments could be tracked and rescheduled by the ARNP. The
AAA surveillance database was maintained on a shared drive
system and could be accessed through any hospital-based
computer by log-in of vascular service personnel.
Study design. Prospective information including pa-
tient demographics and AAA surveillance history was used
along with retrospective medical record review including
perioperative reports and clinic visits to analyze late out-
comes and causes of death determined. Differences in the
presence of medical comorbidities between AAA patients
remaining in surveillance, and those who required opera-
tive repair according to AAA growth or the development of
symptoms were analyzed using 2 calculations. Noncom-
pliance with the clinical pathway was defined as missing no
more than two consecutive imaging appointments as rec-
ommended by the vascular surgeon’s surveillance plan.
Patients were considered lost to follow-up if they declined
AAA surveillance, left the VA Health System, or died. Life
table estimates of completeness of follow-up, patient sur-
vival, and aneurysm-related mortality were performed by
standard methods.
RESULTS
Of 473 patients initially referred with AAA 4.0 cm,
139 had AAA5.4 cm and were considered for immediate
operative repair. Five of these patients had symptomatic
intact or contained ruptures and underwent urgent open
(n 4) or endovascular (n 1) repair. Sixty-four open and
62 endovascular repairs were electively performed for
asymptomatic, intact AAAs 5.4 cm in 126 adequate risk
Fig 1. Abdominal aortic aneurysm surveillance algorithm.patients. Eight extremely high risk patients with asymptom-atic AAAs 6.0 cm required open repair for inadequate
endovascular anatomy. Perioperative (60 days) mortality
for those requiring immediate repair was 5.8% (n 8) with
two of these deaths involving ruptured AAAs. Overall
mortality for immediate repair AAA at our facility during
the study period has been 2.5% with the majority of deaths
resulting from cardiopulmonary conditions.
The remaining 334 patients presenting with AAA 4.0
to 5.4 cm were entered into the surveillance pathway
during the study interval. Mean age (/ SD) of the
overall patient cohort with AAA4.0 cm was 74 8 years
(range 50 to 91 years) with no difference in the average age
of patients presenting with AAA 5.4 cm and those enter-
ing surveillance for AAA 4.0 to 5.4 cm. Table I describes
the patient comorbidities for the cohort. Conditions tradi-
tionally associated with cardiovascular disease (ie, myocar-
dial infarction, hyperlipidemia, and hypertension) reached
statistical significance comparing immediate repairs to pa-
tients enrolled in surveillance suggesting that immediate
repair patients had poorer control of cardiovascular risk
factors as compared to surveillance patients. Duration of
surveillance for enrollees ranged from 6 to 120 months
(mean 34 months 18). The mean size of AAA at the time
of enrollment into surveillance was 4.6 cm 5 with 27% of
AAA being 5.0 cm upon their initial vascular consulta-
tion.
During biannual surveillance imaging, 225 (68%) pa-
tients experienced AAA growth to  5.4 cm (n  218) or
more rapid expansion (1 cm/yr) (n  6) necessitating
surgical intervention at a mean interval of 29 20 months
after entry into surveillance. Two of the six patients expe-
riencing expansion of intact AAAs presented with symp-
toms and required urgent repairs. Aneurysm repair was
accomplished by open surgical graft replacement in 143
patients and endovascular techniques in 82 cases. TwoAAA
ruptures occurred in the surveillance cohort (0.6%). One
high-risk patient with a 5.3 cm AAA presented with a
contained rupture and survived emergent open repair. The
other rupture occurred in a patient with a 5.1 cm AAA who
died at home within 24 hours after evaluation at a civilian
hospital for complaint of back pain that had improved
before discharge. No late AAA ruptures occurred after
endovascular or open repairs. As anticipated, AAA growth
necessitating operative management for patients remaining
in the AAA clinical pathway increased with time. Operative
conversion rates at 1, 3, 5, and 7 years were 38%, 65%, 70%,
and 80%, respectively. Over 7 years of AAA surveillance, the
cumulative rate of operative conversion in the surveillance
population was 68%. Fig 1 illustrates operative intervention
for the surveillance group annually.
Aneurysm-related mortality was low for the surveil-
lance cohort. Two patients undergoing elective open AAA
repair died from perioperative cardiac events resulting in an
overall operative (60 days) mortality of 0.9% in patients
requiring intervention (n 225) during follow-up. Includ-
ing the single fatal AAA rupture without intervention oc-
curring during surveillance (0.3%), cumulative aneurysm-
ured A
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with the AAA surveillance pathway.
By comparison, non-aneurysm related death occurred
in 22 patients in the surveillance cohort (Table II). Cardiac
(2.4%) and cancer-related (2.1%) causes were the most
frequent contributors to late mortality. All cancer-related
deaths occurred after at least 1 year of surveillance with
three of the seven cancer deaths attributed to metastatic
disease. Patient survival during surveillance was 92.4%/
year. Fig 2 summarizes both mortality and compliance
failure.
Patient compliance with the AAA surveillance path-
way was 98.5% during follow-up. Three patients (0.9%)
were lost to follow-up because of patient relocation out
of the region. Two (0.6%) chose elective repair for their
asymptomatic  5.5 cm AAA at civilian hospitals. The
remaining 79 patients with small AAAs have continued
in surveillance. Surveillance enrollment with annual sur-
veillance mortality and compliance is shown in Fig 3.
DISCUSSION
Evidence from prospective clinical trials indicate that
AAA surveillance is safe and cost effective.1-5,10-12 With the
Table I. Patient comorbidities for AAA consultations
Characteristic
Immediate
(CT  5.4
(n  473)
Male 471 (99%)
Coronary artery disease 273 (58%)
Myocardial infarction* 222 (47%)
Congestive heart failure† 9 (2%)
Hypertension 397 (83%)
Hyperlipidemia 341 (72%)
Diabetes mellitus 80 (17%)
Severe COPD 33 (7%)
Active smoking 170 (36%)
Any smoking history 378 (80%)
Renal insufficiency‡ 16 (3%)
AAA, Abdominal aortic aneurysm; COPD, chronic obstructive pulmonary
Forced expiratory volume 30% or oxygen dependent.
*Remote history 6 months.
†American Heart Association class III/IV.
‡Creatinine clearance 50 mg dL.
Table II. Aneurysm-related and non-aneurysm related mo
Group Aneurysm-related†
(n  329)* 3 (0.9%) 8
Surveillance w/repair (n  223) 2
Surveillance (n  106) 1
*334 patients: five patients who left surveillance program.
†Deaths include two postoperative cardiac deaths and one surveillance rupt
‡One death each: age 85, sepsis, bowel perforation, and renal failure.recent recommendations and Medicare approved reim-bursement for AAA screening, vascular centers can expect
an increase in practitioner and patient awareness of the
condition.13 The threshold size associated with a safe rec-
ommendation for continued AAA observation is based on
numerous prospective clinical and population-based natu-
Surveillance group
(CT/US 4.0 – 5.4 cm)
(n  139) (n  334) P value
111 (80%) 162 (49%) .001
93 (67%) 129 (39%) .001
4 (3%) 5 (2%) NS
136 (98%) 261 (78%) .001
98 (71%) 243 (71%) .001
30 (22%) 50 (15%) NS
14 (10%) 19 (6%) NS
92 (66%) 78 (23%) .001
138 (99%) 240 (70%) .001
4 (3%) 12 (4%) NS
e.
ty for patients not lost to follow-up
All cause mortality
iac Pulmonary Cancer Other Total
%) 3 (0.9%) 7 (2.1%) 4 (1%) 25 (7.6%)
3 5 4‡ 18 (8.1%)
0 2 0 7 (6.6%)
AA.
Fig 2. Operative conversions of surveillance enrollees per annum
with all-cause lost to follow-up.repair
cm)
diseasrtali
Card
(2.4
4
4ral history studies demonstrating a significant incremental
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6.0 cm.1-5,10,14-17 We adopted surveillance guidelines val-
idated in the ADAM trial with continued observation used
for 4.0 to 5.4 cm AAA and repair recommended for AAA
5.4 cm.3, 4 Debate is now focused on demonstrating the
optimal method for durable AAA repair (endovascular or
open). Our clinical pathway does not stratify patients for a
particular type of operative repair but relies strictly on
operative planning based on AAA size or expansion criteria.
In this series, virtually no patient was denied an operative
repair based on risk profile alone. Whether or not patterns
AAA expansion can be predicted by clinical pathways such
as this remains unanswered but ongoing small aneurysm
trials such as the Positive Impact of Endovascular Options
for Treating Aneurysms Early (PIVOTAL) trial should
provide important insight as to the benefit early endovas-
cular repair.
In both the UK Small Aneurysm and ADAM trials,1-4
at least two-thirds of patients entering surveillance eventu-
ally required open repair for AAA growth or development
of aneurysm-related symptoms. Our experience was similar
with 68% of patients receiving endovascular or open repair
at a mean interval of 29 months that also mirrored the rate
of disease progression seen in those landmark randomized
trials. In addition, the AAA rupture rate (0.6%) seen during
surveillance of small AAAs using our clinical pathway was
even less than the reported 1% annual rupture risk found
in theUK andADAM trials.When combinedwith only two
operative fatalities after interventions required during AAA
follow-up, the overall aneurysm-related mortality in our
series was extremely low (0.9%). During an equivalent
length of study follow-up as in UK and ADAM trials,
overall patient survival was higher in our experience with
non-aneurysm related deaths far outnumbering those at-
tributed to AAA.
The most important finding of our study is the high
retention/compliance rate (98.5%) of patients achieved
during surveillance of small AAA (4.0 to 5.4 cm). This was
facilitated through an efficient clinical pathway incorporat-
ing continuity of AAA care assured from a single (vascular)
Fig 3. Surveillance enrollment with surveillance mortality and
compliance failure per annum for the study period.provider, daily non-physician provider oversight, prospec-tive database tracking of patients, “patient friendly” sched-
uling of surveillance imaging to reduce repetitive or unnec-
essary travel and clinic visitation, and telephone contact.
Such high patient compliance rates have been achieved in
prospective trials requiring patient consent (and obliga-
tion) to participate and study coordinators to initiate and
arrange follow-up evaluations. Use of a non-physician “fa-
cilitator” (our ARNP) in our pathway was critical to creat-
ing and maintaining patient rapport and motivation during
follow-up by playing a role similar to that of research study
coordinators in formal prospective trials. A 30-day audit of
our clinical pathway revealed that on average our ARNP
staff dedicated 20% of a 40-hour work week towards the
completion of aneurysm consultations and review of cur-
rent AAA in surveillance including updating enrollment
information for the surveillance database which currently
holds 240 small AAA(s). Equally important is a centralized
records system which allows for system-wide, shared infor-
mation within VA health care facilities and reduces the
chance of duplicated or unnecessary studies. By developing
a familiarity with the patient and his medical history, we can
promote a higher degree of customer satisfaction and mo-
tivation which we believe contributed to enhanced reten-
tion in our surveillance program.
We believe that these methods would be applicable in
other high-volume hospital, clinic, or practice systems to
optimize patient safety by “centralizing” small AAA surveil-
lance. Although a potential limitation of the study lies in
how to apply our AAA or other similarly-designed clinical
pathways outside of the controlled veterans health care
environment, several options for offset of added resource
expenditure (eg, salary support for ARNP, database man-
agement) exist. Regional and possibly statewide registries
could be developed in a similar manner to those established
for disease (ie, cancer) or outcome conditions (ie, mortal-
ity). The cost of such programs could be underwritten by
large third party healthcare providers or regional hospital
systems with a focus on reduction of resources for those
institutions. An overall reduction of reimbursements re-
lated to clinic visits would follow because fewer visits are
necessary within the surveillance pathway. Larger hospital
or medical systems could seemore global cost advantages in
reducing numbers of patients experiencing AAA rupture,
emergent/urgent interventions, and extended intensive
care and hospital stays.12 With increasing public/physician
awareness and expansion of AAA screening with now avail-
able reimbursement for directed ultrasound studies, addi-
tional efforts aimed at implementing surveillance pathways
would seem a logical extension to improve AAA care. Even
if not directly performed by vascular surgeons, high-
volume hospital systems, multi-specialty practice groups,
or health maintenance organizations could “centralize”
AAA surveillance for multiple physician providers, elimi-
nate individual provider responsibility for arranging and
assuring completeness of follow-up, and thereby allow the
potential benefits of the pathway to extend to a larger
“pool” of patients. Some revenue generation could also
com from non-physician provider telephone contact with
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99371-3) and for patients requiring repair for AAA growth
during surveillance, documentation of intervention plan-
ning from CT images by the surgeon/operator is also
reimbursable (CPT G0288). Patients experiencing AAA
growth during surveillancemanaged “centrally” could then
be sent back to the referring/assigned providers and their
preferred vascular surgeon/“interventionalist” for appro-
priate AAA treatment. Other common pathological entities
that require serial imaging studies (eg, small pulmonary
nodules or low probability mammographic breast lesions)
could be “centrally” managed by similar surveillance meth-
ods with the resource “tools” described in this report.
Reduction in the variability of care quality, efficiency of
disease management, and improved patient compliance
may all result in safer outcomes.
CONCLUSION
Implementation of a clinical pathway for nonoperative
management of small AAA (4.0 to 5.4 cm) was associated
with high patient compliance, low rupture risk, and ex-
tremely low cumulative aneurysm-related mortality. Aneu-
rysm surveillance can be efficiently performed to achieve
optimal patient safety and could be associated with long-
term resource utilization and cost benefits.
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Dr Marc A. Passman (Nashville, Tenn). Drs Armstrong and
associates should be complimented on an excellent presentation
and well-written manuscript. Based on evidence-based guidelines
and as carryover from their participation in the ADAM trial, a
continued surveillance program was established at James A. Haley
Veterans Hospital in Tampa, Florida, in 1998 for ongoing obser-
vation of small 4.0- to 5.4-cm abdominal aortic aneurysms (AAA).
During the 8-year period, 473 patients were evaluated, of which
139 required operation for AAA exceeding 5.4 cm and 334 en-
tered the surveillance algorithm for AAA of 4.0 to 5.4 cm. For
those within the surveillance program, the authors report onlyaneurysm-related mortality of 0.9% for those following the
surveillance treatment algorithm. This leads me to several
questions.
First, with a captive VA population, a high compliance rate of
98.5% is reported with the surveillance algorithm, which included
CT or ultrasound imaging biannually. While such a compliance
rate is commendable, it may be more difficult to reproduce outside
the VA system. Although some recommendations are provided
based on their VA experience, do the authors have any additional
recommendations for success in the “real world,” where cost and
resources may be more problematic? After all, your group does not
have a comparable program in the university arm of your practice.
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the prevalence or incidence of AAA seems lower in this study than
what would be expected in the general population with a similar
risk profile, which suggests there are either patients with AAA who
are not coming to your attention for enrollment or AAA is being
under-diagnosed. Nationally, there is an increasing attention being
placed on screening for AAA. What measures have the authors
taken to combine their surveillance program with efforts at in-
creased patient and provider awareness in their VA system to
increase screening and identification of AAA, and thereby improve
enrollment into the treatment and surveillance algorithm?
Third, for patients with AAA in the 4.0- to 5.4-cm range
entering the surveillance program, 225 patients (67%) eventually
required operative repair for size exceeding 5.4 cm or expansion
exceeding 1cm/year, of which 143 (or approximately two thirds)
underwent open repair and 82 (approximately one third), endo-
vascular repair. With so many patients eventually requiring opera-
tion, was there any downside to delay now that the patients are
older in terms of increased medical comorbidities compared to
when they entered the program? How many of these patients were
originally an endovascular candidate when entering the surveil-
lance program but with AAA expansion are no longer?
Finally, the threshold size for operation used in the treatment
algorithm is based on evidence based guideline related mostly to
comparison of open repair and surveillance. While randomized
trials comparing endovascular repair and surveillance for small
AAA are still ongoing, early, nonrandomized data from our insti-
tution and others have suggested that endovascular repair of small
AAAs is safe with low risk. Given that 67% of the patients in the
surveillance program eventually required operation, were the au-
thors able to retrospectively identify any factors that predicted
expansion thereby supporting potential earlier AAA repair, espe-cially for those who are endovascular candidates? Again, I congrat-
ulate the authors on their fine presentation and thank the Society
for the privilege of discussing this paper.
Dr Paul A. Armstrong: In response to your first question,
making the transfer of a surveillance program from a socialized
system like the VA to private practice is indeed a challenge, but if
we approach the problem by thinking outside of the box we can
find some creative ways in which to create interest in these pro-
grams and defray cost; for example, regional societies and health
management systems can be petitioned by their members or be
coerced by cost savings to participate. Likewise, legislative pressure
can be levied on third-party payers and health care systems to
provide funding.
In answer to your next question, the primary care providers
within the VA system have a health maintenance menu they
complete at each patient visit. Beginning this year, there has been
an addition to that menu that will include eligibility criteria for
one-time abdominal aneurysm screening. This will provide a clin-
ical reminder, if you will, for our primary providers and likely
increase the effectiveness of aneurysm screening.
In this review, as in others supporting surveillance, aneurysm-
related mortality was a relatively infrequent event. However, we
know that despite operative repair preventing rupture, our older
patients continue to die of other advanced conditions. In this
series, we noted 21 cardiac and 10 cancer deaths within 3 years of
AAA repair; therefore, the question for considering earlier AAA
intervention is an important one. We did not perform a subset
analysis of aneurysm morphology to determine if smaller aneu-
rysms were more amenable to endovascular repair. Instead, we
followed the size and growth parameters of the pathway to deter-
mine final operative options. Thus, I feel this review does little to
support the concept of inviting earlier aneurysm repair.
